MXCT - MAXCYTE - Share Chat

MaxCyte is a leading UK-headquartered life sciences company, pioneering advanced cell-engineering technology. Its proprietary ExPERT™ Flow Electroporation platform provides a highly efficient, scalable, and non-viral method for cell modification, critical for the development and commercialisation of next-generation cell and gene therapies. The platform is widely adopted by global biopharmaceutical companies for drug discovery, clinical development, and commercial manufacturing of complex cell therapies, including CAR-T, CRISPR, and gene-edited products.

MaxCyte operates a strategic licensing model, granting partners access to its technology for specific therapeutic programmes. Revenue is derived from technology access fees, programme milestones, and commercial royalties on approved products utilising the ExPERT system. Positioned at the forefront of cell therapy innovation, MaxCyte plays a crucial role in enabling its partners to bring transformative treatments to market.